Sichuan Clover Biopharma has dosed the first patient in a China Phase I trial of its fully-human TRAIL-Trimer fusion protein in cancer patients with peritoneal carcinomatosis. Clover described PC as a loco-regional disease defined as tumor dissemination inside the peritoneal cavity that often stems from gastrointestinal tumors. SCB-313 is a novel fusion protein consisting of TRAIL (TNF-related apoptosis-inducing ligand) and Clover’s Trimer-Tag©, which allows the molecule to be trimerized. Clover believes its trimerized fusion proteins will be effective against previously undruggable targets.
Source: China Biotoday